Hillstream BioPharma, Inc. (HILS) |
|
0.7916 -0.058 (-6.87%)
|
03-31 16:00 |
|
Open: |
0.8 |
Pre. Close: |
0.85 |
|
High:
|
0.8587 |
Low:
|
0.7732 |
|
Volume:
|
101,406 |
Market Cap:
|
9(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:19:19 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.39  One year: 1.69 |
| Support: |
Support1: 0.77 Support2: 0.64 |
| Resistance: |
Resistance1: 1.19 Resistance2: 1.45 |
| Pivot: |
0.91 |
| Moving Average: |
MA(5): 0.87 MA(20): 0.98
MA(100): 0.75  MA(250): 0.89 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 13.4 %D(3): 18 |
| RSI: |
RSI(14): 36.8 |
| 52-week: |
High: 2.65 Low: 0.3 |
| Average Vol(K): |
3-Month: 3,257 (K) 10-Days: 51 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HILS ] has closed above bottom band by 10.0%. Bollinger Bands are 36.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.95 - 0.96 |
0.96 - 0.96 |
|
Low:
|
0.82 - 0.82 |
0.82 - 0.83 |
|
Close:
|
0.84 - 0.85 |
0.85 - 0.86 |
|
Company Description |
|
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey. |
Headline News |
Tue, 28 Mar 2023
Hillstream BioPharma to Participate in Two Major Industry ... - GlobeNewswire
Thu, 16 Mar 2023
HILLSTREAM BIOPHARMA INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com
Tue, 28 Feb 2023
Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023 - Yahoo Finance
Tue, 21 Feb 2023
Should You Buy Hillstream Biopharma Inc (HILS) Stock After it Is Lower By 34.39% in a Week? - InvestorsObserver
Wed, 15 Feb 2023
Hillstream BioPharma Regains Compliance with Nasdaq Listing ... - GlobeNewswire
Wed, 15 Feb 2023
Hillstream Biopharma regains compliance with Nasdaq - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
12 (M) |
|
% Held by Insiders
|
3.88e+006 (%) |
|
% Held by Institutions
|
56.8 (%) |
|
Shares Short
|
11 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-117.7 |
|
Return on Equity (ttm)
|
-1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-0.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-7 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
92770 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
